Yago Pico de Coaña - Concepedia

Author

Yago Pico de Coaña

Karolinska Institutet ORCID

Also Known As

Pico de Coaña, Yago 1975-, Y PICODECOANA, Y. Pico de Coaña, Yago Pico De Coaña, Yago Pico de Coana, Yago Pico de Coaña

101

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Karolinska Institutet Karolinska University Hospital Heidelberg University German Cancer Research Center Universidad Autónoma de Madrid

About

Yago Pico de Coaña is an author at Karolinska Institutet specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	370
2	Engineering	1	1	10
3	Natural Sciences	1	1	26
4	Biology	1	1	26
5	Biomolecular Engineering	1	1	10

Yago Pico de Coaña

Publications

879

Citations

H-Index

Page 1

	Year	Citations
Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms Yumeng Mao, Isabel Poschke, Erik Wennerberg, Cancer Research Cox-2–dependent MechanismsT-regulatory CellImmunologyImmune RegulationImmunoediting	2013	184
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma Yago Pico de Coaña, Maria Wolodarski, Isabel Poschke, Oncotarget	2017	140
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production Yago Pico de Coaña, Isabel Poschke, Giusy Gentilcore, Cancer Immunology Research	2013	135
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients Rossana Tallerico, Costanza Maria Cristiani, Elina Staaf, OncoImmunology	2016	64
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma Haris Babačić, Janne Lehtiö, Yago Pico de Coaña, Journal for ImmunoTherapy of Cancer	2020	64
Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma Maarten A. Ligtenberg, Yago Pico de Coaña, Taisia Shmushkovich, Molecular Therapy	2018	50
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates Yago Pico de Coaña, Maria Wolodarski, Irene van der Haar Àvila, OncoImmunology Host Pd-l1 ExpressionImmunologyNk CellsPathologyImmunoediting	2020	44
A highly infective Plasmodium vivax strain adapted to Aotus monkeys: Quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development Yago Pico de Coaña, Josefa Rodrı x guez, Eduar Guerrero, Vaccine VaccinationVaccine DevelopmentMalariaImmunologyParasite Control	2003	42
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy Yago Pico de Coaña, Giuseppe Masucci, Johan Hansson, Cancer Immunology Immunotherapy Hematological MalignancyCancer ImmunosurveillanceCtla-4 Blockade TherapyMalignant Blood DisorderHematology	2014	37
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study Jean–Luc Van Laethem, Ivan Borbath, Hans Prenen, The Lancet Oncology OncologyPancreatic CancerMedicineCd40 Agonist MitazalimabImmune Checkpoint Inhibitor	2024	37

Page 1